Navigation Links
Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1

-1, the most treatment-resistant type of HCV, and the majority of patients (74%) had high baseline viral load ( > 800,000 IU/ml), a well-established negative predictive factor for SVR. Patients received daily injections of omega interferon (25 mcg) for up to 48 weeks. The endpoints for this clinical trial were early viral response (EVR), defined as a 2-log reduction in HCV RNA after 12 weeks of treatment, and SVR, defined as undetectable HCV RNA 24 weeks after the end of 48 weeks of treatment. Response rates are presented in the table below:


         HCV RNA Results               Omega IFN + RBV   Omega IFN Alone


    (LOQ= 50 IU/ml)                          N=67              N=35


    Early Viral Response (EVR)               84%               60%

    p= 0.014


    Sustained Viral Response(SVR)            36%               6%

    p= 0.001


With this study, Intarcia also took a step toward testing its hypothesis that maintaining continuous drug levels through daily administration of omega interferon may minimize side effects when compared to current interferon therapies. This study to date has shown that omega interferon is well tolerated with only two discontinuations due to adverse events. Results of this Phase 2 study suggest a favorable overall safety profile with no substantial safety issues being identified. Normalization of serum ALT, a marker of reduced liver inflammation, occurred in 100% of patients achieving SVR and no patients receiving omega interferon with ribavirin experienced relapse during 24 weeks of follow-up after completing 48 weeks of treatment.

Alice Leung, President and Chief Executive Officer of Intarcia stated, "We are developing omega interferon to improve the treatment of HCV by offering a more convenient, potentially safer and more efficacious therapy. Based on the data so far, we believe that a continuous release formulation of omega interferon has the potential to become an important therapy for HCV pat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015  Perrigo Company ... that it has completed the acquisition of leading OTC ... at €200 million. The transaction is a clear demonstration ... the Company,s leading European distribution network spanning 36 countries.  ... Joseph C. Papa commented, "We are excited to ...
(Date:8/28/2015)... 28 de agosto de 2015   Royal ... participación en el  Congreso de la ESC de ... recientes y novedosas, entre ellas HeartModel A.I.  , ... personas y la tecnología con los protocolos de ... los tratamientos y permitir atención en el hogar. ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... CITY, Calif, Oct. 27 Cardica, Inc. (Nasdaq: ... System and its PAS-Port® Proximal Anastomosis System will be ... the Advances in Robotic and Hybrid Coronary Revascularization conference, ... Robotic Surgery and Saint Joseph,s Hospital in Atlanta, Georgia. ...
... YORK, Oct. 27 Delcath Systems, Inc. (Nasdaq: ... host a conference call to discuss its third quarter ... 2010 at 4:30 p.m. ET.  Eamonn Hobbs, President and ... will host the call. The dial-in number for the ...
Cached Medicine Technology:Cardica's Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting 2Cardica's Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting 3Delcath Systems Announces Third Quarter Progress Report Conference Call 2Delcath Systems Announces Third Quarter Progress Report Conference Call 3
(Date:8/29/2015)... ... 2015 , ... "I have been a licensed physical therapist ... in manual therapy, and my invention will provide headache sufferers a solution to ... dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, as ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... extend and improve the lives of patients, according to a newly published report. ... to read the full article. , The authors of the new paper ...
(Date:8/29/2015)... ... 29, 2015 , ... Brands like Toppik , Eau Thermale Avene and ... “Before, a threshold of $49.00 was required to qualify for free standard shipping,” said ... standard shipping for customers regardless of the item’s selling price.” , With competitive pricing ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... include treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma ... position have shown through research to improve treatment outcomes. This localized treatment ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... profit up 138% ... growth, OWINGS MILLS, Md., March 12 Medifast, Inc.,(NYSE: ... year ended December 31, 2007., Financial highlights included:, ... increased 29% compared to the previous year,s ...
... first infected with dangerous germ, , , WEDNESDAY, March 12 (HealthDay ... more with their pets, but one thing you probably never ... staph infection. , However, according to a letter in the ... Medicine , a German family appears to have done just ...
... Idaho, March 12 As previously,disclosed in its Form ... (Nasdaq: NHWK ) announced that Ernest G. Ludy ... company,s Board of Directors for,personal reasons. As a result ... not comply with Nasdaq Marketplace Rule,4350(d)(2) -- which requires ...
... BOTHELL, Wash., March 12 Cardiac Science,Corporation ... in advanced cardiac diagnosis,resuscitation, rehabilitation, and informatics ... the Washington Biotechnology and Biomedical,Association (WBBA) 2008 ... the Bell,Harbor International Conference Center in Seattle. ...
... WEDNESDAY, March 12 (HealthDay News) -- Taking care of someone ... of cardiac disease, a new study finds. , The study ... a heart patient showed that those who provided care all ... psychological strain and less likely to eat heart-healthy diets. , ...
... 2008 (BRONX, NY) The unwanted activation of ... two kidney problems that are major causes of end-stage ... Medicine of Yeshiva University have found. Their research, which ... is described in the March issue of Nature Medicine. ...
Cached Medicine News:Health News:Medifast Announces Year-end 2007 Financial Results 2Health News:Medifast Announces Year-end 2007 Financial Results 3Health News:Medifast Announces Year-end 2007 Financial Results 4Health News:Medifast Announces Year-end 2007 Financial Results 5Health News:Medifast Announces Year-end 2007 Financial Results 6Health News:Medifast Announces Year-end 2007 Financial Results 7Health News:Medifast Announces Year-end 2007 Financial Results 8Health News:Medifast Announces Year-end 2007 Financial Results 9Health News:Woman and Cat Shared 'Super Bug' 2Health News:Woman and Cat Shared 'Super Bug' 3Health News:Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings, Inc. Prompt Notice of Noncompliance from the Nasdaq Global Market 2Health News:Cardiac Science to Present at the Seventh Annual Invest Northwest Conference 2Health News:Caring for Heart Patients Can Strain Hearts 2Health News:Caring for Heart Patients Can Strain Hearts 3Health News:Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment 2
Front protection with choice of adjustable 2" buckle or velcro belt which crosses the back for a comfortable fit. Adjustable straps at shoulders keeps apron snug....
... to help lift the weight off your shoulders ... around protection to cover you front, side and ... a breeze. For additional back support try one ... pressure on the vertebrae and help "lift the ...
... Aprons are the result of a technologically ... x-ray aprons. Constructed with a wear resistant, ... the Lead Free aprons exhibit the same ... Each apron weighs approximately 50% less than ...
... an advanced multi-modality system. The Easy II ... includes our 32-channel digital EEG amplifier with ... channels like airflow, respiratory effort and snoring. ... four DC inputs, a built-in pulse oximeter, ...
Medicine Products: